Finance

Lists
Why is QNCX up 5.16%?
Dive Deeper
QNCX:NASDAQ
Quince Therapeutics Inc
$31.00
+5.16%
(+1.52) 1D
Sep 22, 3:18:11 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for QNCX...
Open
$32.79
High
$32.99
Low
$30.50
Mkt. cap
32.60M
Avg. vol.
23.48K
Volume
18.38K
52-wk high
$909.98
52-wk low
$15.10
EPS
-$125.71
Beta
1.31
Shares outstanding
1.02M
No. of employees
38
Open
$32.79
High
$32.99
Low
$30.50
Mkt. cap
32.60M
Avg. vol.
23.48K
Volume
18.38K
52-wk high
$909.98
52-wk low
$15.10
EPS
-$125.71
Beta
1.31
Shares outstanding
1.02M
No. of employees
38
News stories
From web sources and news partners
About Quince Therapeutics Inc
CEO-
Employees38
Founded2012
HeadquartersSouth San Francisco, California, United States
SectorBiotechnology
Websitequincetx.com
Analyst ratings
Based on 6 analysts giving stock ratings to QNCX in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for QNCX in the last 3 months.
Highest
Current $31.00
$98.00 (+216.13%)
Average
$79.17 (+155.39%)
Lowest
$68.00 (+119.35%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jonathan Wolleben
Citizens JMP
Buy
Upgraded
$77.00
+148.4%
09/22/2026
Albert Lowe
Craig-Hallum
Buy
Initiated
$68.00
+119.4%
08/20/2026
Sam Slutsky
LifeSci Capital
Buy
Maintained
$98.00
+216.1%
08/19/2026
Olivia Brayer
Cantor Fitzgerald
Buy
Reiterated
$70.00
+125.8%
08/17/2026
Mazahir Alimohamed
Oppenheimer
Buy
Reiterated
$82.00
+164.5%
08/17/2026
Joseph Schwartz
Leerink Partners
Buy
Initiated
$80.00
+158.1%
06/24/2026
Jason McCarthy
Maxim Group
Hold
Downgraded
-
-
02/02/2026
Elemer Piros
Lucid Capital
Sell
Downgraded
-
-
01/30/2026
Jason Kolbert
D. Boral Capital
Hold
Downgraded
-
-
01/30/2026
Last report
Aug 14, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$12.31 / -$12.39
+0.62%beat
Revenue / Est. (USD)
- / 0.00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
8.08M
12.60M
6.84M
5.46M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.28M
3.64M
4.27M
16.63M
Operating expense
11.36M
16.24M
11.11M
22.09M
Total operating expenses
11.36M
16.24M
11.11M
22.09M
Operating income
-11.36M
-16.24M
-11.11M
-22.09M
Other non operating income
191.00K
-17.12M
32.84M
3.78M
EBT including unusual items
-13.49M
-36.31M
30.57M
-75.41M
EBT excluding unusual items
-10.87M
-32.65M
21.88M
-17.72M
Income tax expense
-46.00K
3.15M
-5.34M
75.00K
Effective tax rate
0.34%
-8.66%
-17.46%
-0.10%
Other operating expenses
-
-
-
-
Net income
-13.44M
-39.46M
35.91M
-75.49M
Net profit margin
-
-
-
-
Earnings per share
-50.00
-152.00
57.60
-12.15
Interest and investment income
300.00K
227.00K
160.00K
584.00K
Interest expense
-
-
-
-
Net interest expenses
300.00K
227.00K
160.00K
584.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-11.33M
-16.20M
-11.08M
-22.05M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps